Scientists in Germany have made a breakthrough in developing a nasal vaccine that can effectively shut down a COVID-19 infection in the nose and throat, where the virus initially infects the body. In experiments with hamsters, two doses of the weakened live virus vaccine demonstrated "sterilizing immunity" by preventing the virus from replicating, achieving a long-sought goal of pandemic control.
This new approach aims to boost mucosal immunity, targeting the tissues that line the upper airways where the virus enters the body. The idea is to create a strong immune response before the virus can establish itself, much like stationing firefighters under the smoke alarm in your house. This technique has been around since the 1870s and was used for vaccines against anthrax and rabies.
The vaccine, developed with codon pair deoptimization, makes the virus harder to translate by its genetic material, allowing the immune system to recognize it without causing illness. Researchers believe this approach could be more effective than current methods that focus on spike proteins alone.
In animal studies, the nasal vaccine showed promise, outperforming other approaches in both efficacy and safety. While caution is warranted, experts say the results are encouraging and suggest a potential game-changer for COVID-19 prevention.
At least four nasal vaccines for COVID-19 have reached late-stage testing in people, according to the World Health Organization's vaccine tracker. However, respiratory infections remain a tough target for inhaled vaccines, and concerns about safety and efficacy need to be addressed.
The development of this nasal vaccine is not without its challenges. Live attenuated viruses can't be taken by everyone with compromised immunity, and the risks associated with even weakened forms of the virus must be carefully considered. Nevertheless, if successful, this approach could lead to a more effective and longer-lasting immune response against COVID-19.
Several other nasal vaccines are in various stages of development, including ones using adenoviruses and recombinant technology. While some results have been promising, much work remains to be done before these vaccines can be widely adopted. The ongoing pandemic has highlighted the need for new and innovative approaches to prevent infection and protect public health.
This new approach aims to boost mucosal immunity, targeting the tissues that line the upper airways where the virus enters the body. The idea is to create a strong immune response before the virus can establish itself, much like stationing firefighters under the smoke alarm in your house. This technique has been around since the 1870s and was used for vaccines against anthrax and rabies.
The vaccine, developed with codon pair deoptimization, makes the virus harder to translate by its genetic material, allowing the immune system to recognize it without causing illness. Researchers believe this approach could be more effective than current methods that focus on spike proteins alone.
In animal studies, the nasal vaccine showed promise, outperforming other approaches in both efficacy and safety. While caution is warranted, experts say the results are encouraging and suggest a potential game-changer for COVID-19 prevention.
At least four nasal vaccines for COVID-19 have reached late-stage testing in people, according to the World Health Organization's vaccine tracker. However, respiratory infections remain a tough target for inhaled vaccines, and concerns about safety and efficacy need to be addressed.
The development of this nasal vaccine is not without its challenges. Live attenuated viruses can't be taken by everyone with compromised immunity, and the risks associated with even weakened forms of the virus must be carefully considered. Nevertheless, if successful, this approach could lead to a more effective and longer-lasting immune response against COVID-19.
Several other nasal vaccines are in various stages of development, including ones using adenoviruses and recombinant technology. While some results have been promising, much work remains to be done before these vaccines can be widely adopted. The ongoing pandemic has highlighted the need for new and innovative approaches to prevent infection and protect public health.